Beyond Batten Disease Foundation

Join us in our mission to find a cure for Batten disease and prevent hundreds of similar rare genetic diseases that claim the lives of thousands of children every year.

DONATE

Toggle menu

Skip to content
  • About Us

    • About the Foundation

      • Mission and History
      • Board of Directors
      • Staff
      • Founders Circle

    • Funds

      • Alexander’s Fund
      • Bind Up Batten
      • Chase The Cure
      • Delaney’s Dream
      • Hugs for Hudson
      • Iron Will
      • The Isla Edwards Research Fund
      • Nathan’s Batten Battle
      • Rare Sisters
      • Sofia’s Dream
      • Tyler’s Mission
      • Wheelers Warriors Research Fund
      • Will Herndon Fund

    • BBDF’s Role and Impact

      • Latest Updates
      • Batten-1 Treatment
      • The Be Project
      • BE a Hero

    • Contact Us

      Beyond Batten Disease Foundation:

      3305 Steck Ave., Suite 200
      Austin, TX 78757
      Phone: 512.275.2600
      info@beyondbatten.org

      Submit an Inquiry »

  • Understanding Batten

    • About Batten Disease

      • What is Batten?
      • Diagnosis/Symptoms
      • Prognosis
      • Screening
      • Living with Batten

    • Family Stories

      • Family Videos
      • A Mother’s Story
      • Share your Story
      • Batten Map

    • Contact Us

      Beyond Batten Disease Foundation:

      3305 Steck Ave., Suite 200
      Austin, TX 78757
      Phone: 512.275.2600
      info@beyondbatten.org

      Submit an Inquiry »

  • Research

    • What We Know

      • State of the Science
      • CLN3 Gene
      • Screening

    • Foundation Driven

      • Our Strategy
      • Research Activities
      • Batten-1

    • For Researchers

      • About Funding
      • Forms and Instructions
      • Resources

    • Contact Us

      Beyond Batten Disease Foundation
      Phone: 512.275.2600
      Email Us

  • Get Involved

    • OVERVIEW

      • Donate
      • Create a Fundraising Page
      • Create a Fund
      • Volunteer

    • UPCOMING EVENTS

  • A Mother’s Story
  • BBDF Blog

Newsroom

Beyond Batten Disease Foundation  ⁄  Newsroom
16 Sep 2026

THX Pharma and the Beyond Batten Disease Foundation Announce the Grant of a European Patent Protecting the Use of Batten-1 in Juvenile Batten Disease (CLN3)

September 16, 2026
Alejandra Tijerina
Research, News, Press Releases
Lyon, France – Austin, Texas, USA – September 8, 2026 – 6:00 p.m. CEST – THX Pharma (Theranexus), an inno...
Read More
4 Sep 2026

THX Pharma, BBDF and Biocodex Announce Regulatory Submissions for the Phase 3 Clinical Trial of Batten-1 in Juvenile Batten Disease (CLN3)

September 4, 2026
Alejandra Tijerina
Research, News, Press Releases
Lyon, France – Austin, Texas, USA – Gentilly, France – September 1st, 2026 – [TIME] CET – THX Pharma (The...
Read More
16 Jul 2026

BBDF-Funded Clinical Recommendations Mark a Major Milestone for CLN3 Disease Care

July 16, 2026
Alejandra Tijerina
Research, News, Press Releases
Beyond Batten Disease Foundation is proud to share a major milestone for families, clinicians, and resear...
Read More
9 Jun 2026

THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand Together with the CLN3 Batten Community on International Batten Disease Awareness Day

June 9, 2026
Alejandra Tijerina
Research, News, Press Releases
Lyon, France – Gentilly, France – Austin, Texas, United States – June 9, 2026 – 8:00 am CEST – On the occ...
Read More
25 Feb 2026

THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases.

February 25, 2026
Alejandra Tijerina
Research, News, Press Releases
Lyon et Gentilly, France, 10 February 2026, 6.00 pm CET – THX Pharma (Theranexus), a biopharmaceutical co...
Read More
29 Sep 2025

Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercialization of Its Medicines for Rare Diseases

September 29, 2025
Alejandra Tijerina
Research, News, Press Releases
With TX01 and Batten-1, THX Pharma is entering a new strategic phase focused on regulatory approval, earl...
Read More
14 May 2025

Theranexus and Beyond Batten Disease Foundation Announce Strong Positive Real-World Data Supporting Batten-1 Efficacy for the Treatment of Batten Disease

May 14, 2025
Alejandra Tijerina
Research, News, Press Releases
Lyon, France – Austin, Texas, United States – Mai 13, 2025 – 6.00 pm CET –Theranexus, a biopharmaceutica...
Read More
30 Apr 2025

Family Research Calls – May 13 & 15

April 30, 2025
Alejandra Tijerina
Research, News
Dear BBDF Family Partners, Please join us on our next two family research calls. You will need to regi...
Read More
10 Apr 2025

Batten Disease Global Research Initiative Announces Inaugural Grant Recipients

April 10, 2025
Alejandra Tijerina
Research, News
March 18, 2025 Batten Disease Global Research Initiative Announces Inaugural Grant Recipients The B...
Read More
3 Dec 2024

Batten-1 May Preserve Vision with Juvenile Batten Disease

December 3, 2024
Alejandra Tijerina
Research, News
Findings in Phase 1/2 clinical trial, access program also support miglustat's safety. by Margarida Maia,...
Read More
1 2 3 … 30

Recent Posts

  • THX Pharma and the Beyond Batten Disease Foundation Announce the Grant of a European Patent Protecting the Use of Batten-1 in Juvenile Batten Disease (CLN3)
  • THX Pharma, BBDF and Biocodex Announce Regulatory Submissions for the Phase 3 Clinical Trial of Batten-1 in Juvenile Batten Disease (CLN3)
  • BBDF-Funded Clinical Recommendations Mark a Major Milestone for CLN3 Disease Care
  • THX Pharma, Biocodex and the Beyond Batten Disease Foundation Stand Together with the CLN3 Batten Community on International Batten Disease Awareness Day
  • THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases.

Flickr

Categories

  • Research
  • News
  • Press Releases
  • A Mother's Story
  • BE Project
  • Family Stories
  • Videos

Contact Us

  • 512.275.2600
  • info@beyondbatten.org
  • 3305 Steck Ave., Suite 200, Austin Texas, 78757

Connect With Us

What’s New?

  • THX Pharma and the Beyond Batten Disease Foundation Announce the Grant of a European Patent Protecting the Use of Batten-1 in Juvenile Batten Disease (CLN3) September 16, 2026
  • THX Pharma, BBDF and Biocodex Announce Regulatory Submissions for the Phase 3 Clinical Trial of Batten-1 in Juvenile Batten Disease (CLN3) September 4, 2026
  • BBDF-Funded Clinical Recommendations Mark a Major Milestone for CLN3 Disease Care July 16, 2026

Join Our Mailing List

Sign up to get interesting news and updates delivered to your inbox.

GO!
Copyright © 2026 Beyond Batten Disease Foundation. All rights reserved. EIN: 26-3223661